Three children with the hemolytic-uremic syndrome were treated with heparin, aspirin, and dipyridamole. Twoof the children had remained profoundly thrombocytopenic in spite of platelet transfusions and heparin therapy. All three patients responded with prompt elevation of their platelet counts and apparent termination of the pathologic consumption of platelets. Our experience suggests not only that primary platelet consumption may play a critical role in the pathogenesis of the HUS, but also that such patients may benefit from therapy with drugs which inhibit platelet function.
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health